Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4469820 | 0.81 | ROCK2 (0.51) | ROCK2 | |
| SCHEMBL38659331 | 0.79 | ROCK2 (0.55) | ROCK2 | |
| SCHEMBL25176751 | 0.78 | NQO2 (0.47) | NAMPT | |
| SCHEMBL30369597 | 0.78 | NQO2 (0.47) | NAMPT | |
| SCHEMBL1936202 | 0.77 | MGLL (0.55) | NAMPT | |
| SCHEMBL2996602 | 0.75 | CYP4F2 (0.59) | NAMPT | |
| SCHEMBL31539425 | 0.75 | CYP4F2 (0.59) | NAMPT | |
| SCHEMBL30627676 | 0.74 | MAPT (0.57) | — | |
| SCHEMBL28496847 | 0.74 | SMN1; SMN2 (0.56) | — | |
| SCHEMBL4465651 | 0.74 | MGLL (0.51) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | ROCK2 3982/4885NAMPT 3636/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | ROCK2 2861/4885NAMPT 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.